Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
Survey respondents favored maternal vaccination over infant antibody administration, and physician recommendations increased acceptance among some hesitant participants.
The FDA based its approval for adults aged 50 to 64 years on phase 3 trial results, while use in adults aged 65 years and older received accelerated approval.
Mass spectrometry maps biological interactions and environmental signatures across infected cells, global ecosystems, Antarctic soils, and bacterial collections.